HER2-Positive Breast Cancer Market Report 2026

HER2-Positive Breast Cancer Market Overview

• HER2-Positive Breast Cancer market size has reached to $10.93 billion in 2025 • Expected to grow to $15.23 billion in 2030 at a compound annual growth rate (CAGR) of 6.8% • Growth Driver: Impact Of Immunotherapy Adoption On The HER2-Positive Breast Cancer Market • Market Trend: Innovative Therapies In The HER2-Positive Breast Cancer Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under HER2-Positive Breast Cancer Market?

HER2-positive breast cancer refers to a type of breast cancer characterized by the overexpression of the human epidermal growth factor receptor 2 (HER2) protein. This protein promotes the growth of cancer cells and is found in approximately 15-20% of breast cancers. HER2-positive breast cancer is generally more aggressive than HER2-negative forms but is treatable with targeted therapies that inhibit HER2 activity. The main types of treatments for HER2-positive breast cancer are targeted therapy, chemotherapy, endocrine therapy, immunotherapy, and other treatment types. Targeted therapy is a cancer treatment that precisely attacks specific molecules, such as proteins or genes driving cancer growth, while sparing normal cells. These drugs are administered through various routes, including parenteral, oral, and other route of administrations. It is distributed through various channels such as hospital pharmacy, retail pharmacy, and online pharmacy and is used by various end users including hospitals, homecare, specialty clinics, and others.

What Is The HER2-Positive Breast Cancer Market Growth Forecast?

The her2-positive breast cancer market size is expected to see strong growth in the next few years. It will grow to $15.23 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to increasing adoption of next-generation her2 inhibitors, expansion of biosimilar penetration, growing demand for precision oncology treatments, rising investment in targeted cancer research, increasing focus on improving survival outcomes. Major trends in the forecast period include increasing adoption of her2-targeted antibody therapies, growing use of antibody-drug conjugates, expansion of companion diagnostic testing, rising focus on early-stage targeted treatment, enhanced integration of combination therapy approaches.

Global HER2-Positive Breast Cancer Market Segmentation

1) By Treatment Type: Targeted Therapy, Chemotherapy, Endocrine Therapy, Immunotherapy, Other Treatment Types 2) By Route Of Administration: Parenteral, Oral, Other Routes Of Administrations 3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy 4) By End User: Hospitals, Homecare, Specialty Clinics, Other End User Subsegments: 1) By Targeted Therapy: HER2 Inhibitors (Trastuzumab, Pertuzumab), Tyrosine Kinase Inhibitors (TKIs), Antibody-Drug Conjugates (ADC), Small Molecule Inhibitors 2) By Chemotherapy: Anthracycline-based Chemotherapy, Taxane-based Chemotherapy, Platinum-based Chemotherapy, Combination Chemotherapy Regimens 3) By Endocrine Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Estrogen Receptor Antagonists, Estrogen Deprivation Therapy 4) By Immunotherapy: Immune Checkpoint Inhibitors (PD-1/PD-L1 Inhibitors), Monoclonal Antibodies for Immune Modulation 5) By Other Treatment Types: Radiation Therapy, Surgical Interventions (Mastectomy, Breast Conserving Surgery)

What Is The Driver Of The HER2-Positive Breast Cancer Market?

The strong adoption of immunotherapy is expected to propel the growth of the HER2-positive breast cancer market going forward. Immunotherapy refers to a medical treatment that enhances or modifies the immune system's natural ability to fight diseases, such as cancer, infections, and autoimmune disorders. The adoption of immunotherapy is attributed to its capability to enhance the immune system's ability to identify and eliminate cancer cells, providing better efficacy and fewer side effects than conventional treatments. Immunotherapy aids HER2-positive breast cancer by enhancing the body's immune system to recognize and attack HER2-overexpressing cancer cells, improving treatment outcomes and reducing the risk of recurrence. For instance, in July 2023, according to the American Association for Cancer Research, a US-based organization, in 2023, the FDA has approved 11 immune checkpoint inhibitors (ICIs), with at least one ICI authorized for the treatment of 20 different cancer types and for any solid tumor exhibiting specific molecular characteristics. Therefore, the strong adoption of immunotherapy is driving the growth of the HER2-positive breast cancer industry.

Key Players In The Global HER2-Positive Breast Cancer Market

Major companies operating in the her2-positive breast cancer market are F. Hoffmann-La Roche AG, AstraZeneca plc, Novartis International AG, Pfizer Inc., Eli Lilly and Company, Merck & Co. Inc., Amgen Inc., Daiichi Sankyo Co. Ltd., Takeda Pharmaceutical Company Limited, Bristol Myers Squibb, Sanofi S.A., GlaxoSmithKline plc, Bayer AG, Seagen Inc., MacroGenics Inc., BioNTech SE, Incyte Corporation, Zymeworks Inc., Ambrx Biopharma Inc., Mersana Therapeutics Inc.

Global HER2-Positive Breast Cancer Market Trends and Insights

Major companies operating in the HER2-positive breast cancer market are focused on developing innovative therapies, such as her2-directed antibody-drug conjugates (ADCs), to streamline and enhance the treatment process for patients. HER2-directed antibody-drug conjugates (ADCs) are targeted cancer therapies that link an antibody specific to HER2 with a cytotoxic drug, delivering the drug directly to HER2-positive cancer cells for more effective treatment. For instance, in January 2024, AstraZeneca India Pharma Ltd., an India-based biopharmaceutical company, launched Trastuzumab deruxtecan. This innovative therapy was developed through a collaboration between AstraZeneca and Daiichi Sankyo. Trastuzumab deruxtecan is a HER2-directed antibody-drug conjugate (ADC), which delivers a cytotoxic drug directly to HER2-positive cancer cells, offering a more targeted and effective treatment for patients.

What Are Latest Mergers And Acquisitions In The HER2-Positive Breast Cancer Market?

In May 2023, Roche Holding AG, a Switzerland-based pharmaceutical company, acquired rights to Zion’s lead program, ZN-A-1041, for an undisclosed amount. The acquisition aims to advance the development and commercialization of Zion Pharma's ZN-A-1041, a blood-brain-barrier-penetrant HER2 inhibitor, for treating brain metastases in HER2-positive breast cancer patients. Zion Pharma Limited, a China-based biotechnology company that specializes in providing drugs to treat HER2-positive breast cancer.

Regional Outlook

North America was the largest region in the HER2- positive breast cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the HER2-Positive Breast Cancer Market?

The HER2-positive breast cancer market consists of sales of small molecule inhibitors, antibody-drug conjugates, and monoclonal antibodies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the HER2-Positive Breast Cancer Market Report 2026?

The her2-positive breast cancer market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the her2-positive breast cancer industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.